Lisata Therapeutics Inc. Total Assets
Lisata Therapeutics Inc. total assets. Based on the latest financial reports, Lisata Therapeutics Inc. (LSTA) holds total assets worth $11.03 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see LSTA stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Lisata Therapeutics Inc. (1990–2025)
Total assets of Lisata Therapeutics Inc. from 1990 to 2025. This chart illustrates how Lisata Therapeutics Inc.'s total assets have evolved over time, based on quarterly financial data. See current stock price of Lisata Therapeutics Inc. for real-time trading data and today's change.
Lisata Therapeutics Inc. - Asset Composition Analysis
Lisata Therapeutics Inc. Total Assets Breakdown (December 2025)
Lisata Therapeutics Inc. total assets breakdown as of December 2025. Lisata Therapeutics Inc.'s total assets of $11.03 Million consist of 99.8% current assets and 0.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 89.9% |
| Accounts Receivable | $700.00K | 3.9% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1990–2025)
This chart illustrates how Lisata Therapeutics Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore LSTA working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lisata Therapeutics Inc.'s current assets represent 99.8% of total assets in 2025, an increase from 90.9% in 1990.
- Cash Position: Cash and equivalents constituted 89.9% of total assets in 2025, up from 0.0% in 1990.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1990.
- Asset Diversification: The largest asset category is accounts receivable at 3.9% of total assets.
Lisata Therapeutics Inc. Competitors by Total Assets
Key competitors of Lisata Therapeutics Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Lisata Therapeutics Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.69 | 5.77 | 25.08 |
| Quick Ratio | 3.69 | 5.77 | 25.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $8.03 Million | $20.57 Million | $98.03 Million |
Lisata Therapeutics Inc. - Advanced Valuation Insights
This section examines the relationship between Lisata Therapeutics Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.94 |
| Latest Market Cap to Assets Ratio | 0.65 |
| Asset Growth Rate (YoY) | -49.3% |
| Total Assets | $17.74 Million |
| Market Capitalization | $11.45 Million USD |
Valuation Analysis
Below Book Valuation: The market values Lisata Therapeutics Inc.'s assets below their book value (0.65x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Lisata Therapeutics Inc.'s assets decreased by 49.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Lisata Therapeutics Inc. (1990–2025)
The table below shows the annual total assets of Lisata Therapeutics Inc. from 1990 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $17.74 Million | -49.31% |
| 2024-12-31 | $35.00 Million | -36.00% |
| 2023-12-31 | $54.69 Million | -25.11% |
| 2022-12-31 | $73.03 Million | -24.71% |
| 2021-12-31 | $97.01 Million | +169.45% |
| 2020-12-31 | $36.00 Million | +32.59% |
| 2019-12-31 | $27.15 Million | -39.09% |
| 2018-12-31 | $44.58 Million | -29.66% |
| 2017-12-31 | $63.38 Million | +22.27% |
| 2016-12-31 | $51.83 Million | -9.39% |
| 2015-12-31 | $57.21 Million | -54.70% |
| 2014-12-31 | $126.28 Million | +40.59% |
| 2013-12-31 | $89.82 Million | +65.08% |
| 2012-12-31 | $54.41 Million | -64.97% |
| 2011-12-31 | $155.33 Million | +8.60% |
| 2010-12-31 | $143.02 Million | +34.88% |
| 2009-12-31 | $106.03 Million | +5712.30% |
| 2008-12-31 | $1.82 Million | -51.68% |
| 2007-12-31 | $3.78 Million | +215.92% |
| 2006-12-31 | $1.19 Million | +85.94% |
| 2005-12-31 | $642.68K | +546.27% |
| 2004-12-31 | $99.44K | -68.10% |
| 2003-12-31 | $311.69K | -73.66% |
| 2002-12-31 | $1.18 Million | -35.57% |
| 2001-12-31 | $1.84 Million | -60.24% |
| 2000-12-31 | $4.62 Million | -10.69% |
| 1999-12-31 | $5.17 Million | +470.85% |
| 1998-12-31 | $905.79K | +5973.43% |
| 1996-12-31 | $14.91K | -89.05% |
| 1995-12-31 | $136.20K | -98.61% |
| 1994-12-31 | $9.80 Million | +27.27% |
| 1993-12-31 | $7.70 Million | +133.33% |
| 1990-12-31 | $3.30 Million | -- |
About Lisata Therapeutics Inc.
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal ca… Read more